Kristy Wonders
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kristy Wonders has a total of 271 co-authors. Here are the top co-authors by number of shared publications:
- Quentin M. Anstee
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
5 shared publications - Guruprasad Padur Aithal
Department of Hepatology Nottingham University Hospitals NHS Trust Nottingham UK
4 shared publications - Jorn Markus Schattenberg
Department of Medicine II, Saarland University Medical Center, Saarland University, 66421 Homburg, Germany
4 shared publications - Jérôme Boursier
Hepato-Gastroenterology and Digestive Oncology Department, Angers University Hospital, Angers, France
4 shared publications - Mattias Ekstedt
Department of Health, Medicine, and Caring Sciences Linköping University Linköping Sweden
4 shared publications - Michael Pavlides
Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
4 shared publications
Latest Publications
- Open Access
- 19 November 2026
- Published by Springer Nature in Nature Medicine
Author Correction: Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study
- 19 November 2026
- Published by Springer Nature in Nature Medicine
Open AccessAuthor Correction: Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study
- Open Access
- 24 July 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (8) , 2959-2969
Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study
There is a need for robust evaluations of noninvasive biomarkers for metabolic dysfunction-associated steatotic liver disease. This prospective multicenter study assessed the diagnostic accuracy of imaging (including liver stiffness measurement (LSM) using magnetic resonance elastography (MRE) and FibroScan (vibration-controlled transient elastography (VCTE)), serum biomarkers (including NIS2+) and composite scores (including Agile 3+ and Agile 4) for centrally read steatohepatitis and fibrosis. For cirrhosis, several biomarkers exceeded the minimum acceptable performance criterion (MAC), including MRE (area under the receiver operating curve (AUC) 0.91; P < 0.01), VCTE-LSM (AUC 0.87; P < 0.01), Agile 3+ (AUC 0.89; P < 0.01) and Agile 4 (AUC 0.88; P < 0.01). Among 357 participants, fibrosis stages F0–F4 were present in 12%, 16%, 25%, 32% and 15%, respectively. NIS2+ had the highest diagnostic accuracy among serum biomarkers for metabolic dysfunction-associated steatohepatitis (MASH; AUC 0.83) and at-risk MASH (MASH with at least stage 2 fibrosis; AUC 0.82), although neither significantly exceeded the MAC ( P = 0.15 and P = 0.19). Among imaging biomarkers, MRE showed the highest performance for MASH (AUC 0.71) and at-risk MASH (AUC 0.75), but these remained below the MAC. For fibrosis staging, performance was stronger: MRE met the MAC for advanced fibrosis (AUC 0.91; P < 0.01), as did Agile 3+ (AUC 0.84; P = 0.03). For cirrhosis, several biomarkers exceeded the MAC, including MRE (AUC 0.91; P < 0.01), VCTE-LSM (AUC 0.87; P < 0.01), Agile 3+ (AUC 0.89; P < 0.01) and Agile 4 (AUC 0.88; P < 0.01). Serum biomarkers tended to outperform imaging for identifying at-risk MASH, whereas elastography and composite scores showed excellent accuracy for staging advanced fibrosis and cirrhosis.
- 24 July 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (8) , 2959-2969
Open AccessProspective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study
There is a need for robust evaluations of noninvasive biomarkers for metabolic dysfunction-associated steatotic liver disease. This prospective multicenter study assessed the diagnostic accuracy of imaging (including liver stiffness measurement (LSM) using magnetic resonance elastography (MRE) and FibroScan (vibration-controlled transient elastography (VCTE)), serum biomarkers (including NIS2+) and composite scores (including Agile 3+ and Agile 4) for centrally read steatohepatitis and fibrosis. For cirrhosis, several biomarkers exceeded the minimum acceptable performance criterion (MAC), including MRE (area under the receiver operating curve (AUC) 0.91; P < 0.01), VCTE-LSM (AUC 0.87; P < 0.01), Agile 3+ (AUC 0.89; P < 0.01) and Agile 4 (AUC 0.88; P < 0.01). Among 357 participants, fibrosis stages F0–F4 were present in 12%, 16%, 25%, 32% and 15%, respectively. NIS2+ had the highest diagnostic accuracy among serum biomarkers for metabolic dysfunction-associated steatohepatitis (MASH; AUC 0.83) and at-risk MASH (MASH with at least stage 2 fibrosis; AUC 0.82), although neither significantly exceeded the MAC ( P = 0.15 and P = 0.19). Among imaging biomarkers, MRE showed the highest performance for MASH (AUC 0.71) and at-risk MASH (AUC 0.75), but these remained below the MAC. For fibrosis staging, performance was stronger: MRE met the MAC for advanced fibrosis (AUC 0.91; P < 0.01), as did Agile 3+ (AUC 0.84; P = 0.03). For cirrhosis, several biomarkers exceeded the MAC, including MRE (AUC 0.91; P < 0.01), VCTE-LSM (AUC 0.87; P < 0.01), Agile 3+ (AUC 0.89; P < 0.01) and Agile 4 (AUC 0.88; P < 0.01). Serum biomarkers tended to outperform imaging for identifying at-risk MASH, whereas elastography and composite scores showed excellent accuracy for staging advanced fibrosis and cirrhosis.
- Open Access
- 19 January 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (4) , 101737
The Elucidating Pathways of Steatohepatitis (EPoS) staging system: A reproducible 7-tiered fibrosis scoring system in MASLD
- 19 January 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (4) , 101737
Open AccessThe Elucidating Pathways of Steatohepatitis (EPoS) staging system: A reproducible 7-tiered fibrosis scoring system in MASLD
- Open Access
- 4 October 2023
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 134, 107352
Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol
- 4 October 2023
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 134, 107352
Open AccessLiver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol
- Open Access
- 31 March 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 78 (1) , 258-271
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study
Background & Aims: Detecting non-alcoholic steatohepatitis (NASH) remains challenging, while at-risk NASH (steatohepatitis and F≥ 2) tends to progress and is of interest for drug development and clinical application. We developed prediction models by supervised machine learning (ML) techniques, with clinical data and biomarkers to stage and grade non-alcoholic fatty liver disease (NAFLD) patients. Approach & Results: Learning data were collected in the LITMUS Metacohort (966 biopsy-proven NAFLD adults), staged and graded according to NASH-CRN. Conditions of interest were clinical trial definition of NASH (NAS≥ 4;53%), at-risk NASH (NASH with F≥ 2;35%), significant (F≥ 2;47%) and advanced fibrosis (F≥ 3;28%). Thirty-five predictors were included. Missing data were handled by multiple imputation. Data were randomly split into training/validation (75/25) sets. Gradient boosting machine (GBM) was applied to develop two models for each condition: clinical versus extended (clinical and biomarkers). Two variants of the NASH and at-risk NASH models were constructed: direct and composite models. Clinical GBM models for steatosis/inflammation/ballooning had AUCs of 0.94/0.79/0.72. There were no improvements when biomarkers were included. The direct NASH model produced AUCs (clinical/extended) of 0.61/0.65. The composite NASH model performed significantly better (0.71) for both variants. The composite at-risk NASH model had an AUC of 0.83 (clinical and extended), an improvement over the direct model. Significant fibrosis models had AUCs (clinical/extended) of 0.76/0.78. The extended advanced fibrosis model (0.86) performed significantly better than the clinical version (0.82). Conclusions: Detection of NASH and at-risk NASH can be improved by constructing independent ML models for each component, using only clinical predictors. Adding biomarkers only improved accuracy for fibrosis. Export
- 31 March 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 78 (1) , 258-271
Open AccessMachine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study
Background & Aims: Detecting non-alcoholic steatohepatitis (NASH) remains challenging, while at-risk NASH (steatohepatitis and F≥ 2) tends to progress and is of interest for drug development and clinical application. We developed prediction models by supervised machine learning (ML) techniques, with clinical data and biomarkers to stage and grade non-alcoholic fatty liver disease (NAFLD) patients. Approach & Results: Learning data were collected in the LITMUS Metacohort (966 biopsy-proven NAFLD adults), staged and graded according to NASH-CRN. Conditions of interest were clinical trial definition of NASH (NAS≥ 4;53%), at-risk NASH (NASH with F≥ 2;35%), significant (F≥ 2;47%) and advanced fibrosis (F≥ 3;28%). Thirty-five predictors were included. Missing data were handled by multiple imputation. Data were randomly split into training/validation (75/25) sets. Gradient boosting machine (GBM) was applied to develop two models for each condition: clinical versus extended (clinical and biomarkers). Two variants of the NASH and at-risk NASH models were constructed: direct and composite models. Clinical GBM models for steatosis/inflammation/ballooning had AUCs of 0.94/0.79/0.72. There were no improvements when biomarkers were included. The direct NASH model produced AUCs (clinical/extended) of 0.61/0.65. The composite NASH model performed significantly better (0.71) for both variants. The composite at-risk NASH model had an AUC of 0.83 (clinical and extended), an improvement over the direct model. Significant fibrosis models had AUCs (clinical/extended) of 0.76/0.78. The extended advanced fibrosis model (0.86) performed significantly better than the clinical version (0.82). Conclusions: Detection of NASH and at-risk NASH can be improved by constructing independent ML models for each component, using only clinical predictors. Adding biomarkers only improved accuracy for fibrosis. Export